武田制药公司任命朱莉·金为未来的首席执行官,在2026年6月接替克里斯托夫·韦伯. Takeda Pharmaceutical names Julie Kim as CEO-to-be, succeeding Christophe Weber in June 2026.

武田制药公司宣布,美国业务部门现任总裁Julie Kim将于2026年6月接替首席执行官Christophe Weber. Takeda Pharmaceutical has announced that Julie Kim, current president of its U.S. Business Unit, will succeed CEO Christophe Weber in June 2026. Weber自2015年以来一直领导该公司,他即将退休,不会在董事会保留席位。 Weber, who has led the company since 2015, is set to retire and will not retain a seat on the Board. 金先生的任命遵循多年接任程序,需要2026年公司年度股东大会批准。 Kim's appointment follows a multi-year succession process and requires approval at the company's Annual General Shareholders Meeting in 2026.